公开(公告)号：US20250011473A1

公开(公告)日：2025-01-09

申请号：US18755124

申请日：2024-06-26

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph ADAMS ,  Thomas Allen CESKA ,  Anna Marie DAVIES ,  Alistair James HENRY ,  Xiaofeng LIU ,  James Michael MCDONNELL ,  Brian John SUTTON ,  Marta Katarzyna WESTWOOD

IPC: C07K16/42 ,  A61P37/08 ,  C07K14/735 ,  C07K16/28

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：US20220235146A1

公开(公告)日：2022-07-28

申请号：US17541932

申请日：2021-12-03

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph ADAMS ,  Thomas Allen CESKA ,  Anna Marie DAVIES ,  Alistair James HENRY ,  Xiaofeng LIU ,  James Michael MCDONNELL ,  Brian John SUTTON ,  Marta Katarzyna WESTWOOD

IPC: C07K16/42 ,  C07K16/28 ,  C07K14/735 ,  A61P37/08

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).